TNFSF11 Antibody, FITC conjugated

Code CSB-PA023986LC01HU
Size US$299
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name Rabbit anti-Homo sapiens (Human) TNFSF11 Polyclonal antibody
Uniprot No. O14788
Target Names TNFSF11
Alternative Names CD254 antibody; hRANKL2 antibody; ODF antibody; OPGL antibody; OPTB2 antibody; Osteoclast differentiation factor antibody; Osteoprotegerin ligand antibody; RANKL antibody; Receptor activator of NF-kappa-B ligand antibody; Receptor activator of nuclear factor kappa B ligand antibody; Receptor activator of nuclear factor kappa-B ligand antibody; sOdf antibody; soluble form antibody; TNF-related activation-induced cytokine antibody; TNF11_HUMAN antibody; Tnfsf11 antibody; TRANCE antibody; Tumor necrosis factor (ligand) superfamily member 11 antibody; Tumor necrosis factor ligand superfamily member 11 antibody
Raised in Rabbit
Species Reactivity Human
Immunogen Recombinant Human Tumor necrosis factor ligand superfamily member 11 protein (73-306AA)
Immunogen Species Homo sapiens (Human)
Conjugate FITC
Clonality Polyclonal
Isotype IgG
Purification Method >95%, Protein G purified
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form Liquid
Tested Applications ELISA
Protocols ELISA Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Target Data

Function Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy
Gene References into Functions
  1. RANK/RANKL were identified as crucial regulators for BRCA1 mutation-driven breast cancer. Current prevention strategies for BRCA1 mutation carriers are associated with wide-ranging risks; therefore, the search for alternative, non-invasive strategies is of paramount importance PMID: 29241686
  2. High RANKL expression is associated with gastric cancer cell migration. PMID: 30015970
  3. A high level of sRANKL in bronchoalveolar lavage fluid of non-small cell lung cancer patients may predict worse survival. PMID: 29052177
  4. RANKL/OPG ratio was significantly higher in the prolactinoma group than in the control group. PMID: 29895074
  5. RANKL mRNA expression was higher in tumour tissue from patients with metastatic prostate cancer compared to local disease. The RANKL/OPG ratio was low in normal prostate tissue and high in tumours with bone metastases. Expression was high in BPH tissue but did not exceed as much as in the tumour tissue. PMID: 29204705
  6. In cardiovascular risks, OPG serum level might increase as a preventive compensatory mechanism to neutralize the RANKL level increment. The determination of the OPG-RANKL system is a diagnostic indicator for the intensity of vascular calcification and atherosclerosis in SSc patients. PMID: 29336616
  7. sRANKL and OPG may play a role in the pathogenesis of diabetes as well as metabolic disturbance PMID: 28146138
  8. regulation of OSCAR by TNF-alpha and receptor activator of NF kappa beta ligand (RANKL) in pre-osteoclasts/osteoclasts PMID: 28555364
  9. The -643C>T RANKL polymorphism, through its significant influence on body weight and BMI value, may contribute to the development of Osteoporosis in Postmenopausal women. PMID: 27304650
  10. In the present study, we measured expression of RANKL in human periosteum-derived cells(hPDCs) undergoing osteoblastic differentiation and found that expression of RANKL mRNA was markedly increased in these cells in a time-dependent manner.RANKL protein expression was also significantly enhanced in osteogenic-conditioned media from hPDCs undergoing osteoblastic differentiation PMID: 29200953
  11. MiR-217 is a useful diagnostic biomarker and is involved in human podocyte cells apoptosis via targeting TNFSF11 in membranous nephropathy. PMID: 29214160
  12. rs9525641 might contribute to bone mineral density PMID: 28488893
  13. Vascular smooth cells are a significant source of osteoprotegerin within the vasculature but that RANKL, once present, downregulates this production and appears capable of preventing the "protective" upregulation of OPG seen with VSMCs exposed to physiological levels of cyclic strain. PMID: 29635231
  14. receptor activator for nuclear factor-kappa B ligand (RANKL), secreted by human embryonic trophoblasts and maternal decidual stromal cells, polarizes decidual macrophages toward a M2 phenotype. PMID: 29022922
  15. There were no significant associations involving the RANKL gene. Thus, it is suggested that alterations in the OPG and RANK genes are primarily responsible for altering the function and expression of the RANKL ligand, resulting in a predisposition to chronic arthralgia and comorbid temporomandibular OA. PMID: 28464982
  16. Vitamin D, tumor necrosis factor (TNF)-alpha, receptor activator of nuclear factor-KB ligand (RANKL), and OPG levels were determined in GCF and serum. Baseline clinical parameters were similar in all periodontitis groups (P > 0.05) but were higher than that in controls PMID: 28904316
  17. study demonstrated the association of the -643C > T polymorphism with bone mineral density variation and osteoporosis risk in postmenopausal Tunisian women PMID: 28453307
  18. down-regulated miR-143-5p promotes the differentiation of DPSCs into odontoblasts by enhancing Runx2 expression via the OPG/RANKL signaling pathway. PMID: 28608628
  19. OPG and OPG/TRAIL ratio expression were significantly increased in rheumatoid arthritis patients compared to controls (fold change = 1.79, p = 0.013 and 2.07, p = 0.030, respectively), RANKL/OPG ratio was significantly decreased (fold change = 0.50, p = 0.020). No significant differences were found between patients and controls in RANKL and TRAIL expression. PMID: 27403809
  20. Results show that pro-inflammatory cytokines upregulated SOX5 and RANKL expression in both synovial fibroblasts of patients with primary rheumatoid arthritis and cell line. IL-6 facilitates the binding of SOX5 to RANKL promoter. PMID: 27550416
  21. Higher concentrations of serum sRANKL were positively associated with risk of estrogen receptor positive breast cancer. PMID: 28701332
  22. RANKL is overexpressed in invariant NKT cells in bone marrow of patients with multiple myeloma. PMID: 27834938
  23. triple-negative breast cancer (TNBC) patients that expressed both RANK and RANKL proteins had significantly worse RFS and OS than patients with RANK-positive, RANKL-negative tumors. RANKL was an independent, poor prognostic factor for RFS and OS in multivariate analysis in samples that expressed both RANK and RANKL. PMID: 28417335
  24. Findings suggest that cell-autonomous activation of the RANKL/RANK signaling axis is a convergently shared, non-oncogenic addiction underlying the generation and maintenance of CSC-like states in response to diverse molecular events such as BRCA1 haploinsufficiency and EMT phenomena. PMID: 28388533
  25. Data suggest that, in children with type I diabetes, serum levels of osteoprotegerin are up-regulated, serum levels of RANKL are unchanged, and serum levels of fetuin-A are down-regulated. (RANKL = receptor activator of nuclear factor kappa B ligand) PMID: 27028343
  26. There was no significant difference in GCF RANKL values among groups (P > 0.05) or during the observation period (P > 0.008). The use of BP may be effective in preventing periodontal breakdown by controlling the levels of these markers in osteoporosis as an adjunct to periodontal treatment PMID: 28367895
  27. Data report that in postmenopausal women without known genetic predisposition, high RANKL serum levels stratify a subpopulation of women at high risk of developing breast cancer 12-24 months before diagnosis. PMID: 28002811
  28. Data suggest that STAT6 and RANKL are involved in regulation of apoptosis, gene expression, and cell proliferation in hepatocellular carcinoma cell lines; depletion of STAT6 using RNA interference increases apoptosis; this mechanism involves down-regulation of expression of RANKL. (STAT6 = signal transducer and activator of transcription 6; RANKL = receptor activator of nuclear factor kappa B ligand) PMID: 28525794
  29. Positivity of RANKL and anti-CCP2 yielded significant risk for progression with negativity for both as reference. No single nucleotide polymorphism encoding TNFSF11 or SOST was associated with increased concentrations of the factors. PMID: 28190118
  30. The compound with greatest potential is E05657 with high activity and low effective concentration in the HTS system. It increases the OPG/RANKL ratio and OPG secretion, decreases the NFATc1 expression, and reduces osteoclastogenesis in vitro PMID: 27301430
  31. Our study suggests that the RANKL/RANK pathway contributes to the development and maintenance of the immunosuppressive tumor microenvironment and denosumab may be a promising adjuvant therapy targeting TAMs in cancer of apocrine origin PMID: 29277763
  32. RANKL/Osteoprotegerin have roles in bone turnover in Hashimoto Thyroiditis PMID: 27328677
  33. present clear evidence that TRAIL can block several key signalling actions of RANKL in vascular cells, providing further evidence of its vasoprotective potential PMID: 29145460
  34. main finding is that OPG levels decreased significantly during 8 weeks of alcohol abstinence. PMID: 27061293
  35. Studies showed that the central hypothalamic-pituitary regulatory system, via it's relative hormones, seems to control OPG/RANKL/RANK system function, and the pulsatility and circadian rhythmicity of these hormones may induce an oscillatory fluctuation of the OPG/ RANKL ratio. Also, psycological characteristics may provoke a shift of the OPG/ RANKL ratio towards an unbalanced or a balanced status. [review] PMID: 27862210
  36. Studies strongly implicates RANK and RANKL as key molecules involved in the initiation of BRCA1-associated breast cancer. [review] PMID: 27881737
  37. RANK is frequently expressed by cancer cells in contrast with RANKL which is frequently detected in the tumor microenvironment, and together they participate in every step in cancer development. (Review) PMID: 27279652
  38. Proinsulin C-peptide prevents a reduction of type I collagen expression and decreases, in combination with insulin, receptor activator of nuclear factor-kappaB (RANKL) levels. PMID: 28007656
  39. The RANKL/OPG ratio significantly increased in the presence of bone metastasis with appropriate sensitivity and specificity (73% and 72%, respectively) at a cutoff of >/=0.14 for the detection of bone metastasis. Serum OPG and RANKL/OPG ratios are promising biomarkers for detecting bone metastasis in breast cancer patients. PMID: 27983911
  40. Correlations between sRANKL and IL-18 in BALF. PMID: 27826889
  41. RANK/RANKL signaling is involved in the androgen deprivation therapy-induced acceleration of bone metastasis in castration-insensitive prostate cancer and is inhibited by osteoprotegerin to prevent bone metastasis. PMID: 28373003
  42. This study suggested that RANKL could be a marker to differentiate between pagetoid squamous cell carcinoma in situ and extramammary Paget disease . PMID: 27251225
  43. TNF-alpha-converting enzyme -mediated cleavage of soluble RANKL from activated lymphocytes, especially B cells, can promote osteoclastogenesis in periodontitis. PMID: 27815441
  44. RANKL is required for progesterone-mediated cell proliferation in BRCA1mut/+ breast tissue. PMID: 27322743
  45. Results show that RANK-L are overexpressed in human chronic periodontitis which subsequently increase alveolar bone loss. PMID: 27992569
  46. MAOA provides tumor cell growth advantages in the bone microenvironment by stimulating interleukin-6 (IL6) release from osteoblasts, and triggers skeletal colonization by activating osteoclastogenesis through osteoblast production of RANKL and IL6. PMID: 28292438
  47. In this review, we will provide a summary of the biological functions of RANK signaling pathway (receptor activator of nuclear factor kappaB ligand RANKL and its receptor RANK ) and downstream pathways in bone remodeling, immunity and epithelial homeostasis, with a particular emphasis on cancer PMID: 26749530
  48. The results showed that AG490 inhibited (p)-JAK2 and RANKL expression. PMID: 28278513
  49. Review: OPG, RANKL and TRAIL are involved in vascular calcification. PMID: 26924459
  50. Our results suggest that the polymorphism of the RANKL, RANK, and OPG genes does not make a significant genetic contribution to heel ultrasound measurements in a population of young Caucasian adults. Further studies replicating the results in independent populations are needed to support these initial findings. PMID: 28252575
  51. OPG rs2073618, RANK rs75404003, and RANKL rs9594782 single nucleotide poymorphisms may predispose LVH in thalassemia patients. PMID: 28244588
  52. the overexpression of RANKL and high membranous RANKL localization in osteoblasts are related to defective CF transmembrane conductance regulator, and may worsen bone resorption, leading to bone loss in patients with cystic fibrosis. PMID: 27235726
  53. The expression for RANKL and OPG and the RANKL/OPG ratio were not significantly different between symptomatic and asymptomatic periapical lesions. PMID: 27771584
  54. HBOT increased serum OPG levels but receptor activator of nuclear factor kappa-B ligand (RANKL) levels did not change. PMID: 28385082
  55. Preterm neonates exposed to Antenatal Glucocorticosteroid have higher serum levels of OPG, while premature neonates not exposed to Antenatal Glucocorticosteroid have serum OPG and RANKL levels similar to those measured in healthy term neonates. PMID: 26982319
  56. Twenty-one single-nucleotide polymorphisms (SNPs) of TNFSF11, TNFRSF11A, and TNFRSF11B were genotyped. This study suggests that TNFRSF11B but not TNFSF11 and TNFRSF11A genetic polymorphisms are associated with Type 2 Diabetes Mellitus in Southern Han Chinese women. PMID: 27171030
  57. the OPG/RANKL/RANK system might be directly influenced by genetic variants of NOTCH1 in aortic valve calcification. PMID: 28246602
  58. results suggest that serum OPG and RANKL levels are inversely associated with bone loss in men with advanced stage COPD. PMID: 27411457
  59. These data show that the osteoprotegerin and receptor-activator of nuclear factor-kappaB ligand system is associated with bone markers and bone mineral density at the lumbar spine after obesity surgery. PMID: 26438320
  60. the functional expression of RANKL in CD4+/CD8+ T cells and Th17 cells, and the potential role of these cells in chronic obstructive pulmonary disease-associated bone loss was investigated. PMID: 27279356
  61. Tensile force on human macrophage cells promotes osteoclastogenesis through receptor activator of nuclear factor kappaB ligand induction. PMID: 26204845
  62. Postmenopausal women with Rheumatoid Arthritis, carrying either the RANKL-290T allele or possessing the RANK 575CC genotype were more likely to develop osteoporosis. PMID: 26914636
  63. The RANK/RANKL system induces chemoresistance. PMID: 26762414
  64. Our study revealed that RANK-L is a promising marker to forecast pts' prognosis in AML. Immune checkpoint receptor PD-1/L as well as RANK and HLA-ABC did not show an impact on pts' survival. PMID: 27096305
  65. Study identified a novel RANKL function in the promotion of cell adhesion to type I collagen through the RANKL-NF-kappa B-integrin alpha 2 pathway and found integrin alpha2 and RANKL up-regulated in non small cell lung carcinoma. PMID: 27009236
  66. OPG and RANKL polymorphisms were associated with the occurrence of alcohol-induced ONFH. PMID: 27336899
  67. Results demonstrated that the type of inflammatory infiltrate present in periradicular cysts appears to influence the expression of RANK, RANKL, and osteoprotegerin PMID: 25956608
  68. Results showed that the expressions of RANKL and IL-17A were higher in the treatment group than the nontreatment group (P < .05) and higher in males than in females (P < .05). Their increments were well correlated with each other (r = 0.788, P = < .01) but were not time dependent PMID: 25738351
  69. PI3K/Akt pathway stimulates the expressions of RANKL, PTHrP, and BMP-2 partly through NF-kappaB, suggesting its importance for bone metastasis of prostate carcinoma PMID: 27040945
  70. This study demonstrates that clodronate decreases the compression-induced RANKL/OPG ratio expressed by human osteoblasts. PMID: 26446504
  71. High RANKL expression is associated with endometrial metastasis. PMID: 26734994
  72. OPG and RANKL may play an integral role in breast cancer cells homing to the bone environment PMID: 26781475
  73. In conclusion, rheumatoid arthritis synovial fibroblasts were activated by CXCL16 to produce RANKL via pathways involving JAK2/STAT3 and p38/MAPK PMID: 26621504
  74. Alendronate stimulated OPG mRNA and protein expression, but not RANKL expression, in fibroblasts from patients with aseptic loosening following total hip arthroplasty. PMID: 26351115
  75. Atorvastatin treatment reduced circulating osteoprogenitor cells and RANKL expression in T cells, and increased OPG serum levels in postmenopausal osteoporisis. PMID: 26506085
  76. Hypoxia can affect the expression of RANKL and OPG in human periodontal ligament cells PMID: 26722486
  77. Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-kappaB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers PMID: 26629528
  78. expression of OPG, RANK and RANKL genes exert a crucial role in the progression of avascular necrosis PMID: 26617755
  79. IL-29 directly induces RANKL expression in rheumatoid arthritis-fibroblasts like synoviocytes via MAPK signaling pathway. PMID: 26420479
  80. Src expression showed a significantly positive linear relationship with RANK, suggesting a potential mechanism of the RANKL-RANK axis in regulating breast cancer cell differentiation and antiapoptosis. PMID: 26200837
  81. a dual action of HDFCs in osteoclastogenesis; moreover, parathyroid hormone-related protein, CSF-1 and BMP-2 might influence osteoclastogenesis by regulating the expression of RANKL and OPG in HDFCs PMID: 26149648
  82. genetic variation not associated with hypertension in Chinese women PMID: 25810067
  83. the independent and positive (beta = 0.449, p = 0.004, and R(2) = 0.185) association between the OxS marker and RANKL/OPG ratio which was found in osteopenic but not in the other 2 sample groups. PMID: 26635910
  84. Switched memory B cells from RA patients expressed significantly more RANKL compared to healthy controls. B cells supported osteoclast differentiation in vitro in a RANKL-dependent manner. PMID: 26554541
  85. high level of mRANKL/RANK expression in cervical cancer lesions plays an important role in the rapid growth of cervical cancer cells possibly through strengthening the dialogue between cervical cancer cells and regulation of IL-8 secretion PMID: 26398902
  86. Transglutaminase 2 up-regulation is associated with RANKL/OPG pathway PMID: 26133738
  87. The plasma OPG level is negatively associated with nonalcoholic fatty liver disease independent of potential cofounders PMID: 26975539
  88. Mast cell density and expression of MMP-9, RANKL and Ntx correlated positively with of bone disease severity in multiple myeloma patients. PMID: 26894886
  89. higher levels in patients with Rheumatoid Arthritis, decrease correlates with response to Methotrexate therapy and improvement PMID: 25837853
  90. Th17 cytokines have a dual effect on osteoclastogenesis in rheumatoid arthritis (RA): direct induction of osteoclastogenesis from monocytes and up-regulation of RANKL production in RA fibroblast-like synoviocytes (FLSs). PMID: 26362732
  91. Taken together, these results suggested that the expression of RANKL induced by TiPs was mediated by ER stress in fibroblasts. PMID: 26366858
  92. Data show that receptor activator of nuclear factor kappa B ligand (RANKL) was elevated in anti-citrullinated protein antibodies (ACPA)-positive and in anti-cit-vimentin-positive patients with early untreated rheumatoid arthritis (RA). PMID: 26337028
  93. qPCR and in silico hybridization revealed that miR-124 and miR-155 can be directly involved in the transcriptional regulation of Runt-related transcription factor 2 (RUNX2) and receptor activator of nuclear factor kappa-B ligand (RANKL) genes. PMID: 26339601
  94. RANKL Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Breast Cancer. PMID: 26218592
  95. A highly bone metastatic RANKL-overexpressing prostate cancer cell line, LNCaP(RANKL)used as a model to study increased adhesion of prostate cancer (PCa) cells to collagens and found 3-D suspension culture and in vivo PCa tumor growth restore AR through downregulation of AP-4, enhancing integrin alpha2 expression and adhesion to ColI which is rich in bone matrices. PMID: 25200184
  96. The B cell RANKL/OPG ratio correlated significantly with total hip and femoral neck bone mineral density (BMD) PMID: 25393853
  97. These findings suggest that RACK1 specifies the RANKL-stimulated activation of p38 MAPK by facilitating the association of MKK6 with TAK1 PMID: 26038599
  98. Serum RANKL was significantly higher in juvenile-onset anklylosing spondylitis patients than in controls. There was no significant difference in RANKL levels among patients with various HLA-B27 genotypes. PMID: 25912212
  99. The athors show that osteoprotegerin, but not receptor activator for nuclear factor-kappaB ligand, is associated with subclinical coronary atherosclerosis in HIV-infected men. PMID: 26090754
  100. RANKL gene polymorphism is associated with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus. PMID: 25609157

Show More

Hide All

Involvement in disease Osteopetrosis, autosomal recessive 2 (OPTB2)
Subcellular Location Isoform 1: Cell membrane, Single-pass type II membrane protein, SUBCELLULAR LOCATION: Isoform 3: Cell membrane, Single-pass type II membrane protein, SUBCELLULAR LOCATION: Isoform 2: Cytoplasm, SUBCELLULAR LOCATION: Tumor necrosis factor ligand superfamily member 11, soluble form: Secreted
Protein Families Tumor necrosis factor family
Tissue Specificity Highest in the peripheral lymph nodes, weak in spleen, peripheral blood Leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid.
Database Links

HGNC: 11926

OMIM: 259710

KEGG: hsa:8600

STRING: 9606.ENSP00000239849

UniGene: Hs.333791

Most popular with customers


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1